We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+6.05%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
AUM
$2.34B
AUM Growth
-$1.52B
Cap. Flow
-$1.58B
Cap. Flow %
-67.74%
Top 10 Hldgs %
43.48%
Holding
80
New
9
Increased
13
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$115M
2
VTRS icon
Viatris
VTRS
+$114M
3
MGNI icon
Magnite
MGNI
+$24.6M
4
NRG icon
NRG Energy
NRG
+$23.4M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.22%
2 Energy 14.33%
3 Industrials 13.82%
4 Financials 10.76%
5 Utilities 7.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VIRX
76
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
-1,487,385
Closed -$2.36M
HRT
77
DELISTED
HireRight Holdings Corporation
HRT
-1,440,037
Closed -$15.3M
SCTL
78
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
-1,076,587
Closed -$1.28M
KDNY
79
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
-719,809
Closed -$16.7M
CTIC
80
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
-8,963,256
Closed -$37.6M

Similar funds

Rubric Capital Management (New York)'s Q2 2023 Portfolio in Review

As of Q2 2023, Rubric Capital Management (New York) held 80 positions worth $2.34B, down 39% from $3.86B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Rubric Capital Management (New York) withdrew a net $1.58B in Q2 2023, closing 18 positions and reducing 27 holdings. Its most notable exit was First Citizens BancShares, an estimated $51.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 16% a quarter earlier, followed by Energy and Industrials.

Against the trend, Rubric Capital Management (New York) opened a new position in Viatris worth $119M.

  • Rubric Capital Management (New York)'s largest Q2 2023 buy was Viatris: 11,950,000 shares worth $119M.
  • Rubric Capital Management (New York) added most to Teva Pharmaceuticals in Q2 2023, an estimated $115M increase.
  • Rubric Capital Management (New York)'s biggest Q2 2023 reduction was Scorpio Tankers, cutting an estimated $67.8M.
  • Rubric Capital Management (New York) fully exited First Citizens BancShares in Q2 2023, selling an estimated $51.6M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 43% of its $2.34B portfolio in Q2 2023.
  • Rubric Capital Management (New York) opened 9 new positions and closed 18 in Q2 2023.
  • Rubric Capital Management (New York)'s portfolio value fell 39% quarter-over-quarter to $2.34B.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.